3020 POSTER Preliminary efficacy of Bevacizumab with first-line Folfox, Xelox, Folfiri and fluoropyrimidines for mCRC: First BEAT trial

Scott Berry, Eric Van Cutsem(Universitair Ziekenhuis Leuven), M. Mazier(PAREXEL International (France)), Fernando Rivera(Marqués de Valdecilla University Hospital), Beatrix Lutiger(Peter MacCallum Cancer Centre), David Cunningham(Royal Marsden NHS Foundation Trust), Albrecht Kretzschmar(Roche (Switzerland)), Maasberg Michael
European Journal of Cancer Supplements
September 1, 2007
10.1016/s1359-6349(07)70948-5
Cited by 9

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k